Status:
TERMINATED
New Management Strategy of PDA for VLBW Preterm Infants
Lead Sponsor:
China Medical University Hospital
Conditions:
Ductus Arteriosus, Patent
Preterm Infants
Eligibility:
All Genders
Up to 7 years
Phase:
NA
Brief Summary
Patent ductus arteriosus (PDA) is one of the most common complications in premature infants. Successful pharmacological closure of PDA with indomethacin was first reported in 1976. Since then indometh...
Detailed Description
Patent ductus arteriosus (PDA) continues to be one of the most common problems in premature infants. Delayed closure of PDA can impaired renal function with oligouria.The complications are correlated ...
Eligibility Criteria
Inclusion
- Premature infants with birth weight \< 1000 gm
- Premature infants with RDS required IMV
- Echocardiographic evidence of PDA within 12 hours after birth
Exclusion
- Presence of prenatal infection, congenital anomalities and lethal cardiopulmonary status
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00239512
Start Date
March 1 2005
End Date
June 1 2006
Last Update
June 26 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 404-08